2022, Volume 24, Issue 1
Strategic Study of CAE >> 2022, Volume 24, Issue 1 doi: 10.15302/J-SSCAE-2022.01.021
Supervision System of AI-based Software as a Medical Device
1. Institute of Medical-care Information Technology, Hangzhou 311100, China;
2. The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China
Next Previous
Abstract
A scientific supervision system enhances vigorous and standardized development of emerging things. Artificial intelligencebased software as a medical device (AI-Based SaMD) is an important product in the health field enabled by artificial intelligence (AI). As AI develops further, its unique black box algorithm and independent learning ability have posed major supervision challenges. AIBased SaMD supervision needs to keep pace with the times and a more scientific supervision strategy is urgently required to minimize the adverse events of AI-Based SaMD and their risk impact. This article summarizes the current status of supervision systems and supporting resources of AI-Based SaMD in China and abroad considering the difficulties in algorithm change management, quality control, and safety traceability. In addition, we explore the problems and challenges of AI-Based SaMD in China. Furthermore, we suggest that the AI-Based SaMD supervision and support systems should be improved in China to overcome the disadvantages of postmarket supervision.
References
[ 1 ] IMDRF SaMD Working Group. Software as a Medical Device (SaMD): Key definitions [C]. Washington D.C.: IMDRF, 2013.
[ 2 ] Matheny M E, Whicher D, Israni S T. Artificial intelligence in health care: A report from the National Academy of Medicine [J]. The Journal of the American Medical Association, 2020, 323:509– 510. link1
[ 3 ] Benjamens S, Dhunnoo P, Meskó B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: An online database [J]. npj Digital Medicine, 2020, 3(1): 118. link1
[ 4 ] European Commission. ATI - Artificial Intelligence-based software as a medical device [R]. Brussels: European Commission, 2020.
[ 5 ] FDA. Proposed regulatory framework for modifications to Artificial Intelligence/ Machine Learning (AI/ML)—Based Software as a Medical Device (SaMD) [R]. Silver Spring: FDA, 2019.
[ 6 ] IMDRF. Software as a Medical Device: Possible framework for risk categorization and corresponding considerations [C]. Washington D.C.: IMDRF, 2014.
[ 7 ] Abràmoff M D, Lavin P T, Birch M, et al. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices [J]. npj Digital Medicine, 2018, 1: 39. link1
[ 8 ] Yan S, Xu D Z, Ouyang Z L. Analysis on the regulation and Application of United States Intelligence medical device [J]. China Medical Devices, 2021, 36(2): 117–122. Chinese. link1
[ 9 ] FDA. How is the FDA considering regulation of Artificial Intelligence and machine learning medical devices? [R/OL]. (2021-09-21)[2021-11-10]. link1
[10] National Medical Products Administration. Guiding principles for the classification and definition of Artificial Intelligence medical software products [R]. Beijing: National Medical Products Administration, 2021. Chinese.
[11] National Medical Products Administration. Scientific regulatory research has steadily made fruitful results in key projects [N]. China Medical News, 2021-04-15(002). Chinese.
[12] Zhao F, Gao M X, Liu P, et al. Statistics and analysis of 136 cases of adverse events of international medical devices [J]. Chinese Journal of Medical Instrumentation, 2020, 44 (2): 166–171. Chinese. link1
[13] Cai X S, Lyu H, Yu G J. Study on audit guidelines of US FDA medical Artificial Intelligence software [J]. China Digital Medicine, 2019, 14(11): 34–37, 33. Chinese. link1
[14] Ministry of Health, Labour and Welfare (MHLW). Update on medical device and IVD regulation in Japan [R/OL]. (2021-03-20) [2021-11-10]. link1
[15] FDA. Artificial Intelligence/Machine Learning(AI/ML)-Based Software as a Medical Device(SaMD) action plan [R/OL]. (2021-01-15)[2021-11-10]. https://www.fda.gov/media/145022/ download. link1
[16] ITU. Whitepaper for the ITU/WHO focus group on Artificial Intelligence for health [EB/OL]. (2020-10-13)[2021-11-10]. link1
[17] AI4EU.Verifiable and explainable risk forecasting Artificial Intelligence framework [EB/OL]. (2021-11-26)[2021-11-28]. link1
[18] National Institutes for Food and Drug Control. The kick-off meeting of the “Development and application demonstration of the full life cycle testing platform for medical Artificial Intelligence products” was held online [EB/OL]. (2020-08-03)[2021-11-10]. link1
[19] Wang Z F, Huang X L, Yang J，et al. Universal adversarial perturbation generated by attacking layer-wise relevance propagation [C]. New Yok: IEEE, 2020: 431–436.
[20] Wang S Q, Li Y S, Su M L, et al. Medical Artificial Intelligence product application evaluation framework and process research [J]. Chinese Medical Equipment Journal, 2020, 41(1): 62–65. Chinese. link1
京公网安备 11010502051620号
